Investment Rating - The report maintains a positive outlook on the insomnia treatment market, highlighting the potential for new drug sales performance in this sector [20][32]. Core Insights - The insomnia treatment market in China is characterized by a significant unmet need, with over 200 million individuals estimated to suffer from insomnia symptoms, representing a large consumer market potential [16][24]. - The report emphasizes the shift towards innovative insomnia medications, particularly focusing on new types of benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs) as key areas for development [25][38]. - The introduction of new drugs like JY-202 (地达西尼) and DORA medications is expected to reshape the market dynamics, with a forecasted rapid increase in market share and sales [34][39]. Market Overview - The insomnia drug market in China has seen stagnant growth due to a lack of new effective treatments, with the market size in 2023 estimated at 31.62 billion yuan [24]. - The report outlines the historical sales performance of major insomnia medications, indicating a long gap since the last new product launch in 2007, which has contributed to the current market stagnation [24][25]. - The report projects a significant increase in the market size and sales for innovative insomnia drugs, particularly with the anticipated approval and market entry of new products [34][39]. Drug Development Trends - The report identifies two main directions for insomnia drug innovation: improvements on existing BZRAs and the development of DORAs, which are expected to have lower addiction risks and better patient compliance [25][38]. - The new drug JY-202 is highlighted for its selective action on the GABAA receptor, which may reduce side effects associated with traditional insomnia medications [34]. - The report also notes the successful clinical trial results for DORAs, which have shown significant improvements in sleep quality without the risk of addiction, making them suitable for broader consumer use [38][39]. Key Players and Recommendations - The report suggests focusing on companies like 京新药业 (JY-202) and 先声药业 (DORA medications) as they are positioned to capitalize on the emerging market opportunities in insomnia treatment [34][39]. - It recommends monitoring the sales performance of these new drugs as they enter the market, particularly in the context of changing consumer behavior and increasing awareness of sleep health [20][32].

证券研究报告 | 医药生物 | 2025年12月20日 www.hczq.com 华创医药投资观点&研究专题周周谈 ·第155期 失眠治疗蓝海大市场,看好上市新药销售表现 本周专题联系人:朱珂琛 | 华创医药团队： | | | --- | --- | | 首席分析师郑辰 | 执业编号: S0360520110002邮箱: zhengchen@hcyjs.com | | 联席首席分析师刘浩 | 执业编号:S0360520120002邮箱:liuhao@hcyjs.com | | 医疗器械组组长李婵娟 | 执业编号: S0360520110004邮箱: lichanjuan@hcyjs.com | | 中药和流通组组长高初营 | 执业编号: S0360524070002邮箱: gaochulei@hcyjs.com | | 分析师王宏雨 | 执业编号: S0360523080006邮箱:wanghongyu@hcyjs.com | | 分析师朱珂琛 | 执业编号: S0360524070007邮箱: zhukechen@hcyjs.com | | 分析师陈俊威 | 执业编号：S0360525060002邮箱:ch ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 23.54 CNY based on a 22x P/E ratio for 2026 [5][12]. Core Insights - The company is in a rapid growth phase for its core business and key products over the next 1-2 years, with adjustments made to revenue and expense forecasts [5]. - The first innovative drug, Dazisin, has been approved and is expected to perform well commercially, with significant market potential in the insomnia treatment sector [12][42]. - The company has a strong pipeline focusing on central nervous system and lipid-lowering therapies, with promising products in various stages of development [12][22]. Financial Summary - Revenue projections for the company are as follows: - 2023: 3,999 million CNY - 2024: 4,159 million CNY (growth of 4.0%) - 2025: 4,279 million CNY (growth of 2.9%) - 2026: 4,714 million CNY (growth of 10.2%) - 2027: 5,363 million CNY (growth of 13.8%) [7]. - Net profit attributable to the parent company is projected to grow from 619 million CNY in 2023 to 1,079 million CNY in 2027, reflecting a compound annual growth rate of approximately 17.5% [7]. Business Focus - The company has shifted its focus towards innovation after facing challenges from centralized procurement, with a robust pipeline of generic and innovative drugs [12][15]. - The main therapeutic areas include central nervous system disorders, cardiovascular diseases, and digestive system conditions, with a strong emphasis on innovative drug development [15][19]. Product Pipeline - The company has a diverse pipeline with key products such as: - Dazisin (approved for insomnia) - JX11502 (in Phase II for schizophrenia) - JX2201 (in Phase I for high Lp(a) levels) [23][32]. - The company is also pursuing first-generic opportunities for high-value products, such as Calira, which has significant market potential [27][29]. Market Position - The company has established a solid market presence in the CNS and lipid-lowering sectors, with leading market shares in several key products [24][26]. - The innovative drug Dazisin is positioned to capture a significant share of the insomnia treatment market, which has over 200 million patients in China [42][45].

Core Insights - Jingxin Pharmaceutical has achieved hospital coverage of over 1,500 for its drug Didasanib in the first half of the year, indicating a strong market presence and ongoing efforts to enhance patient accessibility [2] Company Summary - The company is actively promoting the hospital admission of Didasanib, which reflects its commitment to improving patient access to this medication [2]

Core Viewpoint - The company is committed to enhancing the sales efforts of its product, Didasyn, aiming to contribute more revenue and profit to the organization [1] Group 1 - The company is actively working to promote the sales of Didasyn [1] - The company expresses its intention to increase revenue and profit through these sales efforts [1]

Core Viewpoint - The company Jingxin Pharmaceutical (002020) is currently facing market fluctuations, with its stock price at 18.02 yuan, down 0.72% as of November 7, 2025, indicating a short-term trading characteristic in the market [1]. Group 1: Company Developments - The company has submitted an application for the approval of its drug, Calcium Chloride, which is expected to enter the National Medical Insurance Directory upon approval [2]. - The company is actively promoting its two major products, Didasyn and Calcium Chloride, which are projected to reach peak sales of several billion yuan in the next 2-3 years [2]. - The sales efforts for Didasyn are ongoing, with the company focusing on hospital admissions and academic promotion activities to enhance patient accessibility [2]. Group 2: Market Activity - On November 7, the net outflow of main funds was 6.74 million yuan, while the net inflow of speculative funds was 10.57 million yuan, indicating a clear short-term speculative trading pattern in the market [2]. - Retail investors experienced a net outflow of 3.82 million yuan on the same day, reflecting a cautious sentiment among smaller investors [2].

Core Viewpoint - The sales efforts for Didasanib by Jingxin Pharmaceutical are proceeding normally, with a focus on enhancing patient accessibility and providing new treatment solutions through hospital admissions and academic promotion activities [1] Company Summary - Jingxin Pharmaceutical (002020) is actively engaged in the sales of Didasanib, indicating a commitment to improving patient access to this treatment option [1]

Core Viewpoint - The National Healthcare Security Administration has announced the 11th batch of centralized drug procurement, which will take place on October 21, covering 55 varieties and 162 specifications, including key areas such as antiviral and kidney disease treatment drugs [1][2]. Group 1: Drug Procurement Policy - The 11th batch of centralized procurement aims to stabilize clinical practices, ensure quality, prevent collusion, and avoid excessive competition [1]. - The new procurement rules will optimize price control mechanisms to prevent companies from underbidding, which previously led to unsustainable low prices [1][4]. - The focus on high-value consumables and medical devices is expected to benefit companies with strong cost advantages and product quality, particularly in major categories like cardiovascular and anti-infection drugs [4][5]. Group 2: Market Opportunities and Challenges - The centralized procurement policy presents both opportunities and challenges for pharmaceutical companies, prompting some generic drug firms to shift towards a combination of generics and innovation [2][5]. - The "anti-involution" trend in the procurement sector is expected to primarily benefit high-value consumables, which have been adversely affected by previous procurement rounds [2][4]. Group 3: Long-term Investment Perspective - Investors are advised to adopt a long-term perspective, as some innovative drug stocks are currently overvalued following previous market enthusiasm [3][9]. - The ongoing improvement of procurement policies is seen as a catalyst for the healthy development of the pharmaceutical industry, favoring large innovative drug companies with strong R&D capabilities [5][9]. Group 4: Company Performance and Projections - Companies like Kelun Pharmaceutical, Jingxin Pharmaceutical, and Fosun Pharma are highlighted for their strong R&D pipelines and potential for growth, with Kelun having over 30 projects focused on oncology [6][7]. - Fosun Pharma has made significant progress in its innovative transformation, with multiple products showing promising clinical trial results [6][8]. - China National Pharmaceutical Group is expected to have nearly 20 innovative products approved in the next three years, with several projected to exceed sales of 2 billion RMB [8].

Macro Strategy - The core viewpoint indicates that the recent cooling of U.S. employment data makes a rate cut in September almost certain, with expectations of a 25bps cut and potential for 1-2 additional cuts throughout the year [1][14][18] - The U.S. non-farm payrolls for August showed an increase of only 22,000, significantly below the expected 75,000, indicating a weakening labor market [1][18] - The unemployment rate rose to 4.324%, slightly above expectations, highlighting a trend of weakening labor demand [1][18] Fixed Income - In the week of September 1-5, 19 green bonds were issued in the interbank and exchange markets, totaling approximately 8.767 billion yuan, an increase of 1.651 billion yuan from the previous week [2] - The secondary market saw a total trading volume of green bonds amounting to 48.2 billion yuan, a decrease of 4 billion yuan from the previous week [2] Industry Analysis - The domestic aluminum electrolytic capacitor industry is experiencing stable growth, with a focus on supercapacitors expected to drive a second growth curve for Jianghai Co., Ltd. [10] - Jianghai Co., Ltd. is positioned as a leader in the supercapacitor market, with a compound annual growth rate of 23.9% in the domestic market from 2017 to 2023 [10] - The report highlights the potential for significant growth in the supercapacitor business, particularly in AI computing applications, as the company collaborates with multiple AI clients [10] Company Recommendations - Yapu Co., Ltd. is expected to see revenue growth from 9.123 billion yuan in 2025 to 10.961 billion yuan in 2027, with a corresponding net profit increase from 575 million yuan to 756 million yuan [9] - Jianghai Co., Ltd. is projected to achieve revenues of 4.565 billion yuan in 2025, growing to 5.770 billion yuan by 2027, with net profits expected to rise from 791 million yuan to 1.025 billion yuan [13] - China Pacific Insurance is maintaining a positive outlook with projected net profits of 51.6 billion yuan in 2025, increasing to 55.3 billion yuan by 2027 [12]

Core Viewpoint - Dongwu Securities report indicates that Jingxin Pharmaceutical focuses on the fields of mental neurology and cardiovascular health, with a positive outlook on its overall performance due to the clearance of finished drug procurement, stabilization of raw materials, and recovery in medical device growth [1] Group 1: Business Focus - Jingxin Pharmaceutical is concentrating on the mental neurology and cardiovascular sectors, which are expected to drive future growth [1] - The company has successfully launched the insomnia drug Dazisni, which is anticipated to gain market traction [1] Group 2: Product Development - The small molecule Lp(a) inhibitor for lowering lipids is progressing well in its research and development, showing potential for international market expansion [1] - The company is expected to see a continuous rollout of innovative drugs, contributing to revenue growth and valuation enhancement [1] Group 3: Financial Outlook - The overall performance of the company is projected to maintain a double-digit growth rate [1] - Given the stable development of existing businesses and the promising progress in innovative drug research, the company is rated with a "buy" recommendation [1]